MDS Pharma Services Establishes Central Lab Testing Facility in Singapore
28 Juli 2004 - 7:01AM
PR Newswire (US)
MDS Pharma Services Establishes Central Lab Testing Facility in
Singapore MONTREAL, July 28 /PRNewswire-FirstCall/ -- MDS Pharma
Services, a leading provider of innovative drug discovery and
development solutions, announces the expansion of its central lab
network with the development of a clinical safety- testing
laboratory in Singapore. This new facility is an extension of the
offerings MDS Pharma Services currently provides in Singapore,
which includes central lab study coordination services, logistics
and global clinical development services. "MDS Pharma Services'
central lab expansion in Singapore is an important step in building
our capabilities in Asia. This new facility is one more example of
our continued investment in expanding MDS Pharma Services'
geographic reach," said Alan Horgan, group vice president, Late
Stage Development. Scott Neilson, vice president and general
manager of MDS Pharma Services central lab, added, "Having a wholly
owned laboratory in Singapore is fundamental to our strategy to
provide consistency and control for our pharmaceutical and biotech
sponsors on a global basis. Singapore is a key location that is
central for the ASEAN (Association of South East Asian Nations)
community. MDS Pharma Services also maintains the only College of
American Pathologists (CAP) accredited central lab in China.
Therefore, the addition of the Singapore location allows the
company to offer unparalleled central lab services across Asia."
The new facility's highlights include: - Safety testing analytical
equipment identical to MDS Pharma Services' other central labs in
Europe and North America; - Scientific leadership from Dr. Tain
Chee Fei, Laboratory Director; - Participation in MDS Pharma
Services' global external QC proficiency testing; - Frozen sample
management facilities with -30 degrees C and -80 degrees C short
and long-term sample storage; - Registration with the CAP and
participation in requirements leading to accreditation; - Licensing
by the Singapore Ministry of Health; - A scalable lab able to
accommodate continued rapid growth of testing for clinical trials
in South and Southeast Asia. While MDS Pharma Services' central lab
has provided central lab testing from Singapore for several years,
this is the company's first wholly owned laboratory testing
facility in this country. The National University Hospital, which
previously provided all of MDS Pharma Services' central lab testing
in Singapore, will continue to provide specialty and esoteric
testing for MDS Pharma Services. MDS Pharma Services offers a full
spectrum of resources to meet the drug discovery and development
needs of the pharmaceutical and biotechnology industries. With
numerous facilities strategically located around the world, the
company applies advanced scientific and technological expertise to
each stage of the drug discovery and development process - early
stage: lead optimization, pre-IND research, pharmaceutical and
biopharmaceutical development, early clinical research
(bioequivalence, phases I-IIa) and bioanalysis; and late stage:
global clinical development (phases IIb-IV) and central lab. For
more information, visit MDS Pharma Services' Web site at
http://www.mdsps.com/. MDS Pharma Services is part of MDS Inc.
(TSX: MDS; NYSE: MDZ), an international health and life sciences
company. At MDS Inc., our 10,000 highly skilled people provide
services, products and instruments enabling health sciences
organizations to enhance the well being of people around the world.
We focus on helping discover and test new drugs, assisting doctors
to diagnose and treat patients and preventing the spread of
disease. Find out more about MDS Inc. (TSX: MDS; NYSE: MDZ), at
http://www.mdsintl.com/ or by calling 1-888-MDS-7222, 24 hours a
day. DATASOURCE: MDS Pharma Services CONTACT: Kim Peacock, MDS
Pharma Services, 621 Rose Street, Lincoln, Neb., Tel: (402)
476-2811, and visit our Web site at http://www.mdsps.com/
Copyright